Medical - Diagnostics & Research
Build Your Comparison
Side-by-side financial analysisStock Comparison
BLLN vs TMO vs DHR vs A vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Banks - Diversified
BLLN vs TMO vs DHR vs A vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Banks - Diversified |
| Market Cap | $4.65B | $174.42B | $127.47B | $36.67B | $896.00B |
| Revenue (TTM) | $355M | $45.20B | $24.78B | $7.23B | $280.33B |
| Net Income (TTM) | $25M | $6.86B | $3.69B | $1.41B | $57.05B |
| Gross Margin | 70.4% | 39.4% | 60.7% | 53.0% | 60.0% |
| Operating Margin | 10.2% | 17.8% | 21.0% | 21.5% | 25.9% |
| Forward P/E | 102.7x | 18.9x | 21.3x | 21.4x | 14.4x |
| Total Debt | $109M | $40.85B | $18.42B | $3.35B | $942.38B |
| Cash & Equiv. | $496M | $9.86B | $4.62B | $1.79B | $343.34B |
BLLN vs TMO vs DHR vs A vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Thermo Fisher Scien… (TMO) | 100 | 129.5 | +29.5% |
| Danaher Corporation (DHR) | 100 | 114.9 | +14.9% |
| Agilent Technologie… (A) | 100 | 146.9 | +46.9% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BLLN vs TMO vs DHR vs A vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BLLN is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 100.0%, EPS growth 106.8%
- 100.0% revenue growth vs DHR's 2.9%
Among these 5 stocks, TMO doesn't own a clear edge in any measured category.
DHR ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
- Beta 0.70, yield 0.7%, current ratio 1.87x
- Beta 0.70 vs BLLN's 1.91
A is the clearest fit if your priority is efficiency.
- 11.1% ROA vs JPM's 1.3%, ROIC 13.5% vs 4.5%
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- 465.8% 10Y total return vs TMO's 219.0%
- PEG 0.81 vs DHR's 35.21
- Lower P/E (14.4x vs 21.4x), PEG 0.81 vs 1.46
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 100.0% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (14.4x vs 21.4x), PEG 0.81 vs 1.46 | |
| Quality / Margins | 20.4% margin vs BLLN's 7.1% | |
| Stability / Safety | Beta 0.70 vs BLLN's 1.91 | |
| Dividends | 1.9% yield, 15-year raise streak, vs DHR's 0.7%, (1 stock pays no dividend) | |
| Momentum (1Y) | +21.8% vs DHR's -11.5% | |
| Efficiency (ROA) | 11.1% ROA vs JPM's 1.3%, ROIC 13.5% vs 4.5% |
BLLN vs TMO vs DHR vs A vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BLLN vs TMO vs DHR vs A vs JPM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 3 of 6 categories
BLLN leads 1 • TMO leads 0 • DHR leads 0 • A leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — BLLN and JPM each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 790.7x BLLN's $355M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to BLLN's 7.1%. On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $355M | $45.2B | $24.8B | $7.2B | $280.3B |
| EBITDAEarnings before interest/tax | $44M | $10.5B | $7.2B | $1.8B | $81.4B |
| Net IncomeAfter-tax profit | $25M | $6.9B | $3.7B | $1.4B | $57.0B |
| Free Cash FlowCash after capex | $28M | $6.7B | $5.3B | $1.3B | $100.9B |
| Gross MarginGross profit ÷ Revenue | +70.4% | +39.4% | +60.7% | +53.0% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +10.2% | +17.8% | +21.0% | +21.5% | +25.9% |
| Net MarginNet income ÷ Revenue | +7.1% | +15.2% | +14.9% | +19.6% | +20.4% |
| FCF MarginFCF ÷ Revenue | +7.9% | +14.9% | +21.4% | +17.4% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +83.8% | +6.2% | +3.7% | +10.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +4.8% | +11.3% | +9.8% | +60.0% | +16.0% |
Valuation Metrics
JPM leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 99% valuation discount to BLLN's 1587.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.7B | $174.4B | $127.5B | $36.7B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $205.4B | $141.3B | $38.2B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | 1587.44x | 26.46x | 35.73x | 28.41x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 102.72x | 18.88x | 21.34x | 21.43x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.53x | 35.21x | 1.93x | 0.90x |
| EV / EBITDAEnterprise value multiple | 266.12x | 18.86x | 18.63x | 21.64x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 15.24x | 3.91x | 5.19x | 5.28x | 3.20x |
| Price / BookPrice ÷ Book value/share | 9.65x | 3.31x | 2.44x | 5.47x | 2.47x |
| Price / FCFMarket cap ÷ FCF | 295.98x | 27.72x | 24.23x | 31.83x | 8.88x |
Profitability & Efficiency
BLLN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
A delivers a 20.8% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $7 for DHR. BLLN carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BLLN scores 7/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.6% | +13.2% | +7.1% | +20.8% | +15.9% |
| ROA (TTM)Return on assets | +5.1% | +6.4% | +4.5% | +11.1% | +1.3% |
| ROICReturn on invested capital | +13.5% | +7.5% | +5.9% | +13.5% | +4.5% |
| ROCEReturn on capital employed | +3.7% | +9.1% | +7.0% | +14.5% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 7 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.23x | 0.76x | 0.35x | 0.50x | 2.60x |
| Net DebtTotal debt minus cash | -$387M | $31.0B | $13.8B | $1.6B | $599.0B |
| Cash & Equiv.Liquid assets | $496M | $9.9B | $4.6B | $1.8B | $343.3B |
| Total DebtShort + long-term debt | $109M | $40.9B | $18.4B | $3.4B | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 516.43x | 5.89x | 18.13x | 15.72x | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $8,449 for DHR. Over the past 12 months, JPM leads with a +21.8% total return vs DHR's -11.5%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs DHR's -4.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.2% | -20.7% | -21.7% | -5.5% | -0.5% |
| 1-Year ReturnPast 12 months | -7.2% | +13.4% | -11.5% | +10.0% | +21.8% |
| 3-Year ReturnCumulative with dividends | -7.2% | -9.5% | -13.0% | +12.0% | +138.2% |
| 5-Year ReturnCumulative with dividends | -7.2% | +1.4% | -15.5% | -6.9% | +118.2% |
| 10-Year ReturnCumulative with dividends | -7.2% | +219.0% | +222.6% | +206.2% | +465.8% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -3.3% | -4.5% | +3.8% | +33.6% |
Risk & Volatility
Evenly matched — DHR and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHR is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 0.91x | 0.70x | 1.06x | 0.94x |
| 52-Week HighHighest price in past year | $138.70 | $643.99 | $242.80 | $160.27 | $337.25 |
| 52-Week LowLowest price in past year | $61.96 | $385.46 | $160.93 | $108.35 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +72.9% | +72.9% | +74.2% | +81.0% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 50.8 | 52.0 | 56.1 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 642K | 2.0M | 4.2M | 1.9M | 7.0M |
Analyst Outlook
JPM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: BLLN as "Buy", TMO as "Buy", DHR as "Buy", A as "Buy", JPM as "Buy". Consensus price targets imply 28.7% upside for DHR (target: $232) vs 5.9% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.86% vs TMO's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $125.00 | $599.70 | $231.80 | $154.75 | $339.75 |
| # AnalystsCovering analysts | 4 | 42 | 43 | 40 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | +0.7% | +0.8% | +1.9% |
| Dividend StreakConsecutive years of raises | — | 8 | 9 | 0 | 15 |
| Dividend / ShareAnnual DPS | — | $1.69 | $1.23 | $0.99 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% | +2.4% | +1.2% | +3.9% |
JPM leads in 3 of 6 categories (Valuation Metrics, Total Returns). BLLN leads in 1 (Profitability & Efficiency). 2 tied.
BLLN vs TMO vs DHR vs A vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BLLN or TMO or DHR or A or JPM a better buy right now?
For growth investors, BillionToOne, Inc.
(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BLLN or TMO or DHR or A or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Danaher Corporation's 35. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — BLLN or TMO or DHR or A or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -15. 5% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BLLN or TMO or DHR or A or JPM?
By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.
70β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately 171% more volatile than DHR relative to the S&P 500. On balance sheet safety, BillionToOne, Inc. (BLLN) carries a lower debt/equity ratio of 23% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — BLLN or TMO or DHR or A or JPM?
By revenue growth (latest reported year), BillionToOne, Inc.
(BLLN) is pulling ahead at 100. 0% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, A leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BLLN or TMO or DHR or A or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 2. 4% for BillionToOne, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 5. 3% for BLLN. At the gross margin level — before operating expenses — BLLN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BLLN or TMO or DHR or A or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Danaher Corporation's 35. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 102. 7x for BillionToOne, Inc. — 88. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 28. 7% to $231. 80.
08Which pays a better dividend — BLLN or TMO or DHR or A or JPM?
In this comparison, JPM (1.
9% yield), A (0. 8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. BLLN does not pay a meaningful dividend and should not be held primarily for income.
09Is BLLN or TMO or DHR or A or JPM better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
70), 0. 7% yield, +222. 6% 10Y return). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHR: +222. 6%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BLLN and TMO and DHR and A and JPM?
These companies operate in different sectors (BLLN (Healthcare) and TMO (Healthcare) and DHR (Healthcare) and A (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BLLN is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; DHR is a mid-cap quality compounder stock; A is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. DHR, A, JPM pay a dividend while BLLN, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.